Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 4/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8308720 | 0.87 | SYK (0.51) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL30729929 | 0.83 | SYK (0.55) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL8308612 | 0.83 | SYK (0.49) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL27096930 | 0.83 | SYK (0.55) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL27310587 | 0.80 | SYK (0.41) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL27299492 | 0.80 | SYK (0.44) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL27097013 | 0.78 | MGMT (0.44) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL29963339 | 0.77 | SYK (0.65) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL6068690 | 0.77 | SYK (0.65) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL21801177 | 0.77 | SYK (0.65) | SYKAURKBINCENPABCB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | SYK 1194/4885AURKB 264/4885INCENP 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.